D
D. Lawrence Wickerham
Researcher at Allegheny General Hospital
Publications - 91
Citations - 30027
D. Lawrence Wickerham is an academic researcher from Allegheny General Hospital. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 48, co-authored 89 publications receiving 27687 citations. Previous affiliations of D. Lawrence Wickerham include University of Pittsburgh & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
TL;DR: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Journal ArticleDOI
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
TL;DR: Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher,Joseph P. Costantino,D. Lawrence Wickerham,Reena S. Cecchini,Walter M. Cronin,André Robidoux,Therese B. Bevers,Maureen T. Kavanah,James N. Atkins,Richard G. Margolese,Carolyn D. Runowicz,Joan James,Leslie G. Ford,Norman Wolmark,Norman Wolmark +14 more
TL;DR: Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer.
Journal ArticleDOI
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Harry D. Bear,Stewart J. Anderson,Ann M. Brown,Roy E. Smith,Eleftherios P. Mamounas,Bernard Fisher,Richard G. Margolese,Heather Theoret,Atilla Soran,D. Lawrence Wickerham,Norman Wolmark +10 more
TL;DR: The addition of four cycles of preoperative docetaxel after four cyclesof preoperative AC significantly increased clinical and pathologic response rates for operable breast cancer.